SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending after a strong earnings report and news of a massive AI lease deal, positioning the company as a key player in AI infrastructure. The community is excited about the potential for a short squeeze and analysts raising price targets, while also debating entry points and long-term prospects. Bullish sentiment is fueled by the company's growth in the AI data center space, with some comparing it to other high-flying stocks in the sector.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is surging due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, fueling speculation about lucrative government contracts. The community is buzzing about the company's growth potential and comparing it to other players in the quantum computing space, with some investors believing LAES is undervalued and predicting a significant climb.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to its potential for a short squeeze, driven by high short interest and growing optimism around its shift towards AI and high-performance computing. Community members highlight Google's backing and the company's advantageous position in the data center sector. Discussions also focus on TeraWulf's potential to catch up with sector peers like CIFR and IREN.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as the community discusses its potential for significant growth, drawing comparisons to IREN's valuation and anticipating news related to AI/HPC ventures. Bullish sentiment is fueled by the company's strong Bitcoin holdings, infrastructure ownership, and a recent mining update, with many expecting a run to higher price targets. Additionally, some are speculating on government involvement and the potential for a short squeeze.

One and one Green Technologies. Inc - Ordinary Shares - Class A

YDDL is trending due to its recent IPO and subsequent volatile price action, with the stock experiencing significant gains and drops. The community is actively discussing its low float, high insider ownership, and potential for both further gains and significant losses, with some expressing concerns about it being a pump and dump. Some traders are also looking at other AI and Green Tech names like $APLD and $HIVE.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the token, emphasizing its roots in internet meme culture. Conversations highlight the potential for high gains and a strong, active community, with many expressing bullish sentiment. There is anticipation for a listing on Moonshot.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as traders discuss its potential for a short squeeze, given its high short interest and Bitcoin's recent price movements. Community members are debating the company's management and future prospects in AI, with some expressing frustration over its performance compared to other miners like CLSK and IREN, while others highlight its large Bitcoin holdings and potential for growth.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to the imminent ticker change to NKLR following its merger with Terra Innovatum, a micro-modular nuclear reactor developer; the change is expected to occur soon. Community members are excited about the potential, drawing comparisons to OKLO and highlighting the growing demand for nuclear energy. Discussions also include the stock's valuation relative to its peers and expectations for increased volume and volatility post-ticker change.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to a recently announced record-breaking hospital contract, sparking significant community interest and a volatile trading environment. Community members are actively discussing the stock's potential for a multi-day run, citing its low float and strong fundamentals, while also debating the likelihood of further price manipulation. The stock's association with other Hong Kong plays is also contributing to the buzz.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending as community members rally behind its narrative of disrupting traditional retirement systems. The coin's ticker and meme-driven approach are generating excitement, with many believing it has the potential for significant growth. Discussions revolve around its strong community, chart consolidation, and the idea of achieving early retirement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

Equity

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.


ETFs to Ride the Small-Cap Comeback Wave 

Rate cut hopes and investor rotation beyond tech are fueling renewed momentum in small-cap stocks, with the Russell 2000 surging in August.

Are Small-Cap ETFs Finally Ready to Shine?

IWM is gaining momentum as rate-cut hopes, attractive valuations and rising small-business optimism fuel renewed interest in small-cap ETFs.


Should Schwab U.S. Small-Cap ETF (SCHA) Be on Your Investing Radar?

Shares of uniQure N.V. (QURE) were in the spotlight on Friday morning after its first quarter (Q1) revenue fell 81% year-on-year (YoY) while losses narrowed.The gene therapy company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/09/3078125/0/en/uniQure-Announces-First-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html">reported</a> revenue for the three months ended March of $1.6 million, compared to $8.5 million in the same period of 2024, and below an analyst estimate of $6.71 million, as per Finchat data.The company attributed the revenue fall to a decrease of $4 million in contract manufacturing of HEMGENIX gene therapy for biotherapeutics company CSL Behring, among other factors.uniQure, however, narrowed its quarterly loss to $0.82 per share, compared to a loss of $1.36 in the corresponding period of 2024. Analysts were estimating a loss of $1.06 per share.The narrowing of the net loss in the quarter was driven by a significant reduction in the company’s operating expenses, as it slashed employee-related expenses, facility expenses, and costs related to preclinical supplies.The firm ended the quarter with cash, cash equivalents, and current investment securities of approximately $409 million, expected to fund its operations into the second half of 2027.The company is now seeking U.S. FDA approval for its AMT-130 gene therapy as a treatment for Huntington’s disease.CEO Matt Kapusta said that the company expects to provide a regulatory update on AMT-130 in the second quarter, including guidance on the potential timing for its application to the FDA seeking approval to distribute the therapy.On Stocktwits, retail sentiment around uniQure remained unmoved within the ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_8_08_00_AM_png_281dbf2952.webp" alt="QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE/sentiment">QURE stock</a> declined by 32% this year but is up by about 142% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-reports-positive-data-from-cancer-drug-trial/chiWpd3RblJ">AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 

Goldman Sachs resumes coverage on European Internet & Media, sees 22% upside

Investing.com -- Goldman Sachs has resumed coverage on 24 European Internet and Media stocks, estimating an average upside of 22% across the sector.

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following disappointing quarterly earnings, but retail investors held their bullish ground.Sangamo reported a fourth-quarter adjusted loss per share of $0.11, narrowing significantly from a loss of $0.34 a year earlier. However, this was worse than Wall Street's expected $0.09 per share loss.Revenue of $7.6 million also fell short of the consensus estimate of $11.7 million.&nbsp;CEO Sandy Macrae emphasized the company's progress over the past year, notably securing FDA approval for clinical trials of ST-503, a potential treatment for idiopathic small fiber neuropathy (iSFN)."We believe our neurology pipeline represents important potential value. In addition, we continue to engage in Fabry business development negotiations, in an effort to capitalize the business for the future," he said.Macrae added that 2025 will be a pivotal year, with plans to begin patient enrollment and dosing for the iSFN clinical study by midyear.&nbsp;The company also aims to submit a Biologics License Application (BLA) for its Fabry disease program in the second half of the year.On Stocktwits, sentiment for Sangamo ended Monday on an 'extremely bullish' note, with message volume exploding by 1200% from a day earlier.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMO_sentiment_and_message_volume_as_of_March_17_png_2c103aadf6.webp" alt="SGMO sentiment and message volume as of March 17.png" width="1316" height="302"><figcaption>SGMO sentiment and message volume as of March 17. | source: Stocktwits</figcaption></figure>Several optimistic users expressed confidence in Macrae's remarks about securing a third potential agreement with a major pharmaceutical company for its adeno-associated virus (AAV) capsid, STAC-BBB. The technology is designed to enhance the delivery of intravenously administered genomic medicines for specific neurological conditions.Sangamo has already licensed STAC-BBB to Roche's Genentech and Astellas Pharma.<stembedurl>https://stocktwits.com/BurkeTheBizarre15/message/608344985</stembedurl><stembedurl>https://stocktwits.com/Who_is_JohnnyGalt/message/608344869</stembedurl>Sangamo has been under pressure since December, when Pfizer ended a hemophilia drug development partnership, citing slow patient uptake for such therapies.Shares of the company have shed only about 1% this year but are up 20% over the past 12 months.According to Koyfin, five out of eight analysts covering the stock rate it 'buy' or 'strong buy', while the rest recommend 'hold'.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Affirm Holdings (AFRM) stock gained 13.3% in premarket trade on Friday after the company reported a surprise quarterly profit and its revenue topped Wall Street estimates.The firm reported a net income of $80.36 million, or $0.23 per share, for the fiscal second quarter, compared with a loss of $166.90 million, or $0.54 per share, in the year-ago quarter.&nbsp;Analysts were expecting a loss of $0.17 per share, according to Koyfin data.The buy now, pay later firm’s revenue jumped 46.6% to $866.4 million, exceeding the Street estimate of $807.6 million.The company said its gross merchandising volume (GMV), which implies the total value of all the transactions processed by Affirm, jumped 35% to $10.1 billion.Affirm attributed the rise to strong performance in the general merchandise and consumer electronics categories due to the strong holiday shopping season.Its active consumers rose 23% to 21 million, and its active merchant count grew 21% to 337,000.The company said its direct-to-consumer GMV rose 43% to $2.8 billion, with active Affirm cardholder count rising about 20% quarter over quarter.However, its allowances for credit losses rose to 5.4% from 5% in the year-ago quarter.Affirm forecast fiscal 2025 revenue between $3.13 and $3.19 billion and GMV between $34.74 and $35.34 billion.According to TheFly, following Thursday's earnings report, several brokerages raised the price target for the stock.Wells Fargo raised its price target on the stock to $85 from $70. The brokerage said that while no particular key performance indicator outshined the rest, a broad-based strength would help drive the company’s earnings performance better than any other firm in its coverage.Retail sentiment on Stocktwits moved higher in the ‘extremely bullish’ (92/100) territory than a day ago, while retail chatter remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:799/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AFRM_Feb_7_ae0eafab22.JPG" alt="AFRM’s Sentiment Meter and Message Volume as of 07:58 a.m. ET on Feb. 7, 2025 | Source: Stocktwits" width="799" height="177"><figcaption>AFRM’s Sentiment Meter and Message Volume as of 07:58 a.m. ET on Feb. 7, 2025 | Source: Stocktwits</figcaption></figure>One retail trader said that companies such as Affirm have emerged as the alternative for financial credit for many.<stembedurl>https://stocktwits.com/agente360/message/603286370</stembedurl>Over the past year, <a href="https://stocktwits.com/symbol/AFRM">Affirm stock</a> has gained 38.4%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/honeywells-3-way-split-draws-mixed-response-from-wall-street/chPzN2eRss">Honeywell’s 3-Way Split Draws Mixed Response From Wall Street: Retail Exudes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Affirm Holdings, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on December 24, 2024. (Photo by Jaque Silva/NurPhoto via Getty Images)

Affirms Holdings Stock Surges Premarket After Surprise Profit, Upbeat Q2 Revenue: Retail’s Extremely Bullish

The buy now, pay later firm’s revenue jumped 46.6% to $866.4 million, exceeding the Street estimate of $807.6 million.

Schibsted drops after earnings miss, Jefferies calls it a difficult quarter

Children’s Place Inc. (<a class="mention" data-mention="$PLCE" data-symbol-id="PLCE" href="https://stocktwits.com/symbol/PLCE" target="_blank">$PLCE</a>) stock was up nearly 10% on Thursday after the specialty retailer focused on children, announced a new brick-and-mortar store in the New Jersey state, ahead of the holiday shopping season and its third quarter results, lifting retail sentiment.The new ‘Gymboree’ store, located at the Garden State Plaza in Paramus, N.J. signals a “new era of growth and innovation,” said the company, adding it aims to blend curated collections of premium children’s apparel and accessories.“This is more than a store launch; it’s the beginning of a bright new chapter for Gymboree,” Claudia Lima-Guinehut, Brand President for Children's Place, said in a statement.Retail sentiment on the stock was extremely bullish (83/100), an improvement from the ‘bearish’ mood (34/100) a week ago. Message volumes climbed to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_at_1_46_03_PM_343a190194.png" alt="Screenshot 2024-11-22 at 1.46.03 PM.png" width="1304" height="290"><figcaption>PLCE sentiment and message volumes on Nov 22 as of 3:05 am ET| Source: Stocktwits</figcaption></figure>Children’s Place third-quarter earnings are expected on Nov 27. Wall Street analysts expect earnings per share (EPS) to come in at $2.43 on estimated revenues of $423.41 million.Many Stockwits users are bullish on the stock with some noting considerable volatility in the stock price.<stembedurl>https://stocktwits.com/nyfan29/message/593546490</stembedurl><stembedurl>https://stocktwits.com/MonkeyMan24/message/593557256</stembedurl>On Thursday, UBS lowered the price target for Children’s Place stock to $17 from $18, and kept a ‘Neutral’ rating on its shares, The Fly <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=PLCE">reported.</a> The firm reportedly said it “sees more downside risk than upside going into the Q3 report.”Children’s Place operates as a global retail and wholesale network that includes two digital storefronts, more than 500 stores in North America, and other wholesale marketplaces. It distributes in 15 countries through five international franchise partners.Its brands include The Children’s Place, Gymboree, Sugar &amp; Jade, and PJ Place.Children’s Place stock is down 29% year-to-date.For updates and corrections, email newsroom@stocktwits.com&nbsp;&nbsp;

Many Stockwits users are bullish on the stock with some noting considerable volatility in the stock price.|Souce: Pixabay

Children’s Place Stock Rises After New Brick-And-Mortar Store Launch: Retail Upbeat

Retail sentiment on the stock improved to ‘extremely bullish’ from ‘bearish.’

Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$28.04
Prev Close	$28.28
Open	$28.25
Dividend Yield	N/A
50-Day Moving Average	$27.19
Beta	N/A
Avg. Volume	4.55M
PE Ratio	N/A

52-Week High	$28.57
52-Week Low	$20.04
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

SCHA
Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SCHA News

SCHASchwab Strategic Trust - Schwab U.S. Small-Cap ETF